ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 542

Incidence and Prevalence of Interstitial Lung Disease in the US Population and in Patients with RA By Anti-Citrullinated Protein Antibody Status

Evo Alemao1, Roshini Indrakumar2, Aarti Rao2 and Ying Bao1, 1Bristol-Myers Squibb, Princeton, NJ, 2Mu Sigma, Bangalore, India

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ACPA, interstitial lung disease and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) is recognized as the most common pulmonary extra-articular manifestation of RA. The hazard ratio for 30-year risk of ILD in patients with RA (vs a matched cohort of patients without RA) is 8.96 (95% CI: 4.02, 19.94).1 A recent meta-analysis concluded that anti-citrullinated protein antibody (ACPA) positivity was associated with an increased risk of lung disease (pooled odds ratio: 2.6).2 The objective of this analysis was to evaluate the prevalence and incidence of ILD by ACPA levels in general and in the population with RA.

Methods: Data from July 1, 2002, to September 30, 2017, from administrative claims database Optum® Clinformatics™ Data Mart were used. Patients with ACPA test information were included in the analysis; the date of the test was the index date for the general cohort and first RA diagnosis date was index date for the RA cohort. The RA cohort comprised patients having ≥2 claims for RA and an ACPA test. Patients in the general and RA cohorts were divided into groups based on median ACPA titer values. Identification of patients with ILD was based on a published algorithm that included a two-step process: an initial diagnosis code of ILD, then a code for chest X-ray or CT scan on or after the first ILD diagnosis, and a second chest X-ray or CT scan after the first scan. Incidence rates (IRs) and prevalence rates were calculated for both cohorts and by subgroups based on ACPA levels.

Results: A total of 177,728 patients with ACPA information were identified (overall cohort); of those 20,746 (11.7%) and 156,982 (88.3%) were ACPA+ and ACPA−, respectively. A total of 9827 patients with RA had ACPA information (RA cohort); of whom 2927 (29.8%) and 6900 (70.2%) were ACPA+ and ACPA−, respectively. The prevalence of ILD in the overall cohort was 5.3% versus 8.2% in the RA cohort. The ILD IRs were higher in the ACPA+ versus the ACPA− group in the overall cohort (13.3 vs 8.4 per 1000 patient-years) as well as in the RA cohort (12.9 vs 11.7 per 1000 patient-years). In addition, the ILD IRs were greater for patients with higher ACPA titers in the overall cohort (Table 1).

Conclusion: The prevalence of ILD in patients with RA was higher than that in the general population. The ILD prevalence and IRs were higher in ACPA+ patients and increased with ACPA titer in the overall cohort. Further analysis with a larger RA cohort is required to confirm these findings.

References:

  1. Bongartz T, et al. Arthritis Rheum 2010;62:1583–91.
  2. Zhu J, et al. J Rheumatol 2014;41:1282−9.

Table 1. Incidence and prevalence of ILD by ACPA status and titers

Total patients

Patients with ILD

Prevalence, %

Incident ILD

IR per 1000 PY

Overall cohort

N

177,728

9466

5.3

2778

9.0

ACPA− patients

156,982

7871

5.0

2308

8.4

ACPA+ patients

20,746

1595

7.7

470

13.3

By ACPA titer groups for ACPA+ patients in overall cohort

Group 1 (≤41.30)

10,379

753

7.3

213

12.1

Group 2 (>41.30)

10,367

842

8.1

257

14.5

RA cohort

n

9827

807

8.2

263

12.0

ACPA− patients

6900

559

8.1

184

11.7

ACPA+ patients

2927

248

8.5

79

12.9

By ACPA titer groups for ACPA+ patients in RA cohort

Group 1 (≤52.00)

1473

127

8.6

40

13.0

Group 2 (>52.00)

1454

121

8.3

39

12.7

ACPA=anti-citrullinated protein antibody; ILD=interstitial lung disease; IR=incidence rate; PY=patient-years


Disclosure: E. Alemao, Bristol-Myers Squibb, 1, 3; R. Indrakumar, Mu-sigma, 5; A. Rao, Mu Sigma for Bristol-Myers Squibb, 5; Y. Bao, Bristol-Myers Squibb, 1, 3.

To cite this abstract in AMA style:

Alemao E, Indrakumar R, Rao A, Bao Y. Incidence and Prevalence of Interstitial Lung Disease in the US Population and in Patients with RA By Anti-Citrullinated Protein Antibody Status [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/incidence-and-prevalence-of-interstitial-lung-disease-in-the-us-population-and-in-patients-with-ra-by-anti-citrullinated-protein-antibody-status/. Accessed February 2, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-prevalence-of-interstitial-lung-disease-in-the-us-population-and-in-patients-with-ra-by-anti-citrullinated-protein-antibody-status/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences